智通财经APP获悉，再鼎医药(09688)尾盘涨近5%，截至发稿，涨4.21%，报32.15港元，成交额3.35亿港元。
消息面上，再鼎医药近日公布有关ZL-1310的正面数据，加上美国FDA已授出快速通道认证(Fast Track Designation)，集团计划今年下半年开展第二类小细胞肺癌(2L SCLC)的第三阶段关键研究。美银表示，基于以上临床进展，将集团2027年收入及净利润预测分别上调2.5%及14%。
浦银国际认为，ZL-1310有望凭借不错的疗效数据及优秀的安全性数据在SCLC适应症上实现差异化竞争。年内后续ZL-1310催化剂包括：2L+ SCLC关键注册性临床有望于2H25开启，预计将以1.6mg/kg作为剂量（仍需取得FDA同意），1LSCLC数据读出（预计2025年底），潜在出海授权机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.